Status:
COMPLETED
11ß-HSD1 and Metabolic Syndrome
Lead Sponsor:
Charite University, Berlin, Germany
Conditions:
Metabolic Syndrome
Impaired Glucose Tolerance
Eligibility:
All Genders
20-65 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether the insulin sensitizing effects of rosiglitazone were accompanied by changes in 11ß-HSD1 expression and activity in different tissues. Furthermore the...
Detailed Description
The PPARgamma agonist rosiglitazone (R) increases insulin sensitivity, which is comparable to the effects of a reduction in 11ß-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activity in animal models...
Eligibility Criteria
Inclusion
- Impaired glucose tolerance
Exclusion
- Treatment with insulin
- Orally taken antidiabetic medication, glucocorticoids or vitamin K-antagonists
- Heart failure
- Impaired hepatic or renal function
- Anaemia
- Disturbed coagulation
- Any other endocrine disorder
Key Trial Info
Start Date :
May 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00370305
Start Date
May 1 2004
End Date
October 1 2008
Last Update
January 16 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Charite, Campus Benjamin Franklin
Berlin, Germany, 12200